Posted by Michael Wonder on 03 Jul 2018
Deloitte survey finds biopharma companies are accelerating adoption of real-world evidence
28 June 2018 - A recent survey shows that 90% of biopharma companies are making significant investments in real-world evidence capabilities to support multiple annual objectives that include driving drug development and meeting regulatory requirements.
The findings of Deloitte’s second annual life sciences industry’s real-world evidence (RWE) capabilities show how the importance of how the use of RWE has evolved across the industry and how has impacted the application of real-world data. Real world evidence, as defined by the U.S. FDA is “the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD.
The survey was conducted to shed light on how biopharmaceutical companies’ approach to optimise the use of RWE across the enterprise is changing through investments, functional applications and technology," Deloitte said.
